Investment Thesis
CURIS is a biopharmaceutical company with zero revenue, mounting losses (-$24.2M net income), and negative operating cash flow of -$9.0M per period, indicating a severely distressed business model. While the company maintains a debt-free balance sheet with $15.0M in cash, the burn rate suggests runway of only 12-24 months with no clear path to profitability or revenue generation.
Strengths
- Zero long-term debt with clean balance sheet structure
- Maintains $15.0M in cash reserves representing 50% of total assets
- Adequate current liquidity ratio of 1.11x to cover near-term obligations
Risks
- Zero revenue generation with declining YoY trends and no commercialization path visible
- Massive net losses of -$24.2M with severely negative cash flow of -$9.0M indicating 12-24 month cash runway
- Negative returns on equity (-190%) and assets (-81%) destroying shareholder value at accelerating rate
Key Metrics to Watch
- Quarterly revenue generation and commercial progress on product pipeline
- Operating cash flow trend and actual quarterly cash burn rate
- Cash reserves depletion relative to remaining operational runway
Financial Metrics
Revenue
0.0
Net Income
-24.2M
EPS (Diluted)
$-1.25
Free Cash Flow
-9.0M
Total Assets
29.7M
Cash
15.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-190.4%
ROA
-81.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.11x
Quick Ratio
1.11x
Debt/Equity
0.00x
Debt/Assets
57.2%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T06:48:59.629072 |
Data as of: 2026-03-31 |
Powered by Claude AI